Takeda Pharmaceutical Co Ltd (4502.T)
4,930JPY
8:28pm EDT
¥-20 (-0.40%)
¥4,950
¥4,945
¥4,960
¥4,925
650,500
3,642,137
¥5,520
¥3,225
4502.T
About
Overall
| Beta: | 0.57 |
| Market Cap (Mil.): | ¥3,912,796.00 |
| Shares Outstanding (Mil.): | 789.67 |
| Dividend: | 90.00 |
| Yield (%): | 3.63 |
Financials
| 4502.T | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 29.81 | 35.66 | 35.83 |
| EPS (TTM): | 166.23 | -- | -- |
| ROI: | 4.42 | 19.36 | 18.72 |
| ROE: | 6.29 | 20.07 | 19.54 |
Lundbeck says drug shows improvement in depression symptoms
COPENHAGEN, May 18 - Danish pharmaceutical group Lundbeck and Japanese partner Takeda said on Saturday that data from clinical phase III studies with the antidepressant vortioxetine had shown significant improvement in patients' symptoms.
NPS regains right to drugs from Takeda for $50 mln in NPS shares
March 19 - NPS Pharmaceuticals Inc has regained full worldwide rights to a pair of drugs from Japan's Takeda Pharmaceutical Co in exchange for $50 million in NPS common shares, the companies announced on Tuesday.
BRIEF-Takeda submits marketing authorisation application for vedolizumab in European union
LONDON, March 8 - Takeda Pharmaceutical Co Ltd : * Submits marketing authorisation application for vedolizumab in moderately to
Affymax, Takeda recall anemia drug Omontys after deaths
TOKYO/WASHINGTON - U.S.-based Affymax Inc and Japan's Takeda Pharmaceutical Co said they are voluntarily recalling all lots of anemia treatment Omontys (peginesatide) in the United States due to reports of serious hypersensitivity reactions, including some deaths.
UPDATE 1-Affymax, Takeda recall anemia drug Omontys after deaths
TOKYO/WASHINGTON, Feb 24 - U.S.-based Affymax Inc and Japan's Takeda Pharmaceutical Co said they are voluntarily recalling all lots of anemia treatment Omontys (peginesatide) in the United States due to reports of serious hypersensitivity reactions, including some deaths.
Affymax, Takeda recall anaemia drug Omontys after deaths
TOKYO, Feb 24 - U.S. Affymax Inc. and Japan's Takeda Pharmaceutical Co said they are voluntarily recalling all lots of anaemia treatment Omontys (peginesatide) in the U.S., due to reports of serious hypersensitivity reactions, including some deaths.
FDA approves three type 2 diabetes pills from Takeda
- U.S. health regulators approved Takeda Pharmaceutical Co's alogliptin to treat type 2 diabetes as a standalone drug and in two other formulations in combination pills with older diabetes medicines.
UPDATE 1-FDA approves three type 2 diabetes pills from Takeda
* Standalone to be sold as Nesina, combos as Kazano, Oseni
FDA approves three type 2 diabetes pills from Takeda
Jan 25 - U.S. health regulators approved Takeda Pharmaceutical Co's alogliptin to treat type 2 diabetes as a standalone drug and in two other formulations in combination pills with older diabetes medicines.
Lundbeck gets U.S. nod for antidepressant submission
COPENHAGEN - Danish pharmaceutical group H Lundbeck A/S said on Wednesday the U.S. Food and Drug Administration (FDA) has accepted the submission of a new drug application for an antidepressant.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Wright Reports
|
$483.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
